Full CoverageTop news
Regulators Approve Lenacapavir for H.I.V. Prevention
By Apoorva Mandavilli
The world's only twice-a-year shot to prevent HIV could stop transmission — if people can get it
By Lauran Neergaard
FDA approves powerful HIV prevention drug: What to know about Yeztugo
By Benjamin Ryan
Posts on X
Formerly Twitter
Gilead Sciences
GileadSciences
#GileadNews: In an open letter, Chairman and Chief Executive Officer Daniel O’Day discusses our just-approved #HIV prevention medication and its role in our fight to help end the epidemic: gilead.inc/3TuzsrI pic.x.com/NMOFSHpX0a
Posted on X
Gilead Sciences
GileadSciences
Congratulations to Gilead’s Tomas Cihlar who received the 2025 Warren Alpert Foundation Prize for his scientific leadership in the development of a novel HIV medication that has the potential to change the landscape in HIV prevention and treatment. pic.x.com/awblsm27Fp
Posted on X
UNAIDS Global
UNAIDS
✍️@Guardian | Lenacapavir, twice-yearly HIV prevention injection could cost just $25 per patient a year, say researchers—yet may be priced at 1000x more.
This medicine could help end the HIV pandemic.
We urge @GileadSciences: Do the right thing. Make it affordable. Save lives.
Posted on X
UNAIDS Global
UNAIDS
A fully funded UNAIDS means protecting decades of progress in the global HIV response and driving the momentum we need to finally end AIDS by 2030.
Here's how⬇️
www.unaids.org/en/donate
#InvestinUNAIDS
Posted on X
All coverage
HIV prevention drug hailed as a 'breakthrough' gets FDA approval : Goats and Soda
By Jonathan Lambert
Gilead won U.S. approval for HIV prevention shot, but when will low-income countries gain sufficient access?
By Ed Silverman
Gilead Wins Historic Approval for Twice-Yearly HIV Drug
By Dan Samorodnitsky
FDA approves Gilead's twice-yearly HIV prevention injection, offering a powerful and convenient new option
By Annika Kim Constantino
FDA approves new twice-yearly HIV shot. What to know
By Ken Alltucker
FDA Approves “Breakthrough” HIV Drug
By Jackie Flynn Mogensen
FDA Approves Gilead’s HIV Shot. It Works 99.9% of the Time.
By Josh Nathan-kazis
FDA approves twice-a-year injection for HIV prevention
By Jacqueline Howard
FDA signs off on Gilead's landmark long-acting PrEP med, signaling new era in HIV prevention
By Zoey Becker
Gilead’s Twice-a-Year HIV Prevention Shot Wins FDA Approval
By Robert Langreth
Revolutionary New Drug Offers 99.9% Protection Against HIV
By Nikhil Pandey
US FDA approves Gilead's twice-yearly injection for HIV prevention
By Deena Beasley & Julie Steenhuysen
Lenacapavir Offers Promising Step Forward in HIV Prevention: Q&A With Onyema Ogbuagu, MBBCh, FACP, FIDSA
By Onyema Ogbuagu & Julia Bonavitacola
Another tool in the fight against HIV — and more
By Lourdes Duarte, Patrick Elwood & Katharin Czink
New HIV Prevention Drug Approved—Now Let’s Remove the Final Barrier
By Jeffrey A. Singer
Injectable HIV Prevention Drug Gets FDA Nod
By Heidi Splete
FDA approves 6-month HIV prevention shot
By Joseph Choi
HIV protection with just two shots a year: FDA approves Gilead drug
By Jason Mast & Ed Silverman
FDA approves the world's only twice-a-year shot to prevent HIV
By Lauran Neergaard
US regulators approve ‘miracle’ HIV drug
By Tom Chivers
HIV shot: Food and Drug Administration approves the world's only twice-a-year shot to prevent HIV
By Lauran Neergaard
FDA Approves the World's only Twice-A-Year Shot to Prevent HIV
By Lauran Neergaard